Amanta Healthcare
September 1, 2025 – September 3, 2025
| Price | ₹0 - ₹0 |
| Premium | ₹0 |
|---|---|
| Lot size | 0 |
| Allotment | Sep 4, 2025 |
| Listing | Sep 8, 2025 |
Amanta Healthcare About
IPO Details
| Total Issue Size | 1,00,00,000 shares (aggregating up to * Cr) |
| Fresh Issue | 1,00,00,000 shares (aggregating up to * Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 2,88,29,351 shares |
| Share Holding Post Issue | 4,13,29,351 shares |
IPO Reservation
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not less than 15.00% of the Net Issue |
Key Performance Indicator (KPI)
| KPI | FISCAL-25 | FISCAL-24 | FISCAL-23 |
|---|---|---|---|
| ROE | 12.42% | 5.27% | -3.27% |
| ROCE | 13.72% | 12.76% | 12.19% |
| DEBT/EQUITY | 2.02 | 3.1 | 3.43 |
Company Financial ( In ₹Crore)
| Period Ended | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.7 |
| Profit After Tax | 10.5 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| Net Worth | 96.39 | 66.29 | 62.88 |
| Reserves and Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195 | 205.23 | 215.66 |
Peer Comparison
Details will be added soon.
About Compay
- Incorporation: December 1994
- Industry: Pharmaceuticals & Medical Devices
- Specialization: Development, manufacturing, and marketing of sterile liquid products, primarily parenteral products.
- Key Technologies:
- Aseptic Blow-Fill-Seal (ABFS)
- Injection Stretch Blow Moulding (ISBM)
Product Portfolio
- Pharmaceutical Products:
- Fluid therapy formulations (IV fluids, diluents)
- Ophthalmic solutions
- Respiratory care products
- Medical Devices:
- Irrigation solutions
- First-aid products
- Eye lubricants
Business Operations :
- Operates through three main business units:
- National Sales
- International Sales
- Product Partnering (with Indian and foreign pharmaceutical companies)
- Manufactures 45+ generic products, marketed under its own brands in India through a network of 189 distributors and stockists.
Global Presence :
- Products registered in 19 countries.
- Exports branded products to 19 countries, including Africa, Latin America, and the UK.
- Fully compliant with multiple international regulations.
Strength
Rising Healthcare Awareness: Growing access to healthcare, medicines, and health insurance in India supports strong demand for pharmaceuticals.
Government Support: Favorable policies like the PLI scheme, tax incentives, and infrastructure subsidies boost industry growth.
Skilled Talent Pool: India benefits from a large base of scientists, researchers, and engineers, strengthening its pharmaceutical capabilities.
Weakness
Single Manufacturing Facility Risk: Dependence on one facility in Gujarat exposes operations to disruptions from power shortages, accidents, natural disasters, or other unforeseen events.
Production & Quality Risks: Delays, quality issues, or failure to deliver products on time may lead to order cancellations and loss of clients or distributors.
Amanta Healthcare Lead Manager(s)
Amanta Healthcare Address
8th Floor, Shaligram Corporates
C.J. Marg
Ambli,
Ahmedabad, Gujarat, 380058
Phone: 079 67777600
Email: cs@amanta.co.in
Website: https://www.amanta.co.in/
Amanta Healthcare Registrar
MUFG Intime India Private Limited (Link Intime)
Link Intime India Private Ltd
C 101, 247 Park,
L.B.S.Marg Vikhroli (West),
Mumbai - 400083